- Home
- HFBL vs OTLK Comparison
HFBL vs OTLK Comparison
Compare HFBL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- OTLK
- Stock Information
- Founded
- HFBL 1924
- OTLK 2010
- Country
- HFBL United States
- OTLK United States
- Employees
- HFBL N/A
- OTLK N/A
- Industry
- HFBL Savings Institutions
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HFBL Finance
- OTLK Health Care
- Exchange
- HFBL Nasdaq
- OTLK Nasdaq
- Market Cap
- HFBL 41.6M
- OTLK 42.8M
- IPO Year
- HFBL N/A
- OTLK 2016
- Fundamental
- Price
- HFBL $14.54
- OTLK $1.42
- Analyst Decision
- HFBL
- OTLK Buy
- Analyst Count
- HFBL 0
- OTLK 5
- Target Price
- HFBL N/A
- OTLK $5.25
- AVG Volume (30 Days)
- HFBL 1.8K
- OTLK 2.6M
- Earning Date
- HFBL 10-23-2025
- OTLK 08-14-2025
- Dividend Yield
- HFBL 3.70%
- OTLK N/A
- EPS Growth
- HFBL 35.20
- OTLK N/A
- EPS
- HFBL 1.47
- OTLK N/A
- Revenue
- HFBL $21,720,000.00
- OTLK $1,505,322.00
- Revenue This Year
- HFBL N/A
- OTLK N/A
- Revenue Next Year
- HFBL N/A
- OTLK $342.80
- P/E Ratio
- HFBL $9.94
- OTLK N/A
- Revenue Growth
- HFBL 10.10
- OTLK N/A
- 52 Week Low
- HFBL $11.75
- OTLK $0.79
- 52 Week High
- HFBL $14.86
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- HFBL 71.13
- OTLK 56.44
- Support Level
- HFBL $14.00
- OTLK $1.28
- Resistance Level
- HFBL $14.20
- OTLK $1.48
- Average True Range (ATR)
- HFBL 0.11
- OTLK 0.12
- MACD
- HFBL 0.02
- OTLK 0.02
- Stochastic Oscillator
- HFBL 72.41
- OTLK 67.32
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.